Phacilitate Leaders Forum

17th - 18th SEPTEMBER 2019



Mark Throsby

Mark Throsby

CSO, Merus N.V.

Dr. Mark Throsby joined Merus in October 2008 with responsibility for coordinating preclinical research and external alliances. Prior to joining Merus, Dr. Throsby was 8 years at Crucell in various R&D capacities culminating in the role Director of Antibody R&D from 2006 to 2008. Before joining Crucell Dr. Throsby was an associate investigator with CNRS at Hôpital Necker in Paris for 4 years and prior to that held an MRC of Canada Post-Doctoral Fellowship at the University of Toronto. Dr. Throsby graduated in immunology from Monash University, Melbourne Australia and received his PhD from the Department of Medicine, Monash University, Australia. 

  • Real thinking forward combining experts in the field from manufacturing, regulatory and value vision” – “great network with strong experience and sharing risks & opportunities
    Jean-Philippe Combal
    GenSight Biologics
  • The conference consistently proves to be a great forum for networking with industry leaders in the development of cellular and gene therapies as well as vendors for important technologies and services.
    Michael Covington
    Juno Therapeutics, Inc
  • It was a very interesting event as all participants, including speakers were ready to exchange, even on the most challenging subjects such as reimbursement, GMP guidance
    Bertrand Alexandre
  • Phacilitate EU delivered it's promise and more, the topics discussed were highly relevant, with very good and professional speakers and panelists. You will see me next year in Berlin.
    Dr Ohad Karnieli
    Karnieli Ltd